Literature DB >> 23449271

Early high-dose daptomycin for methicillin-resistant Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentrations: ready for prime time?

Adam Weston, Helen W Boucher.   

Abstract

Entities:  

Keywords:  MRSA; bloodstream infection; daptomycin; methicillin-resistant Staphylococcus aureus; vancomycin

Mesh：

Substances：

Year:  2013        PMID： 23449271      PMCID： PMC3641867          DOI： 10.1093/cid/cit118

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  14 in total

1.  Detection of vancomycin-intermediate Staphylococcus aureus with the updated Trek-Sensititre System and the MicroScan System. Comparison with results from the conventional Etest and CLSI standardized MIC methods.

Authors:  Rohan Nadarajah; Linda R Post; Catherine Liu; Steven A Miller; Daniel F Sahm; Geo F Brooks
Journal:  Am J Clin Pathol       Date:  2010-06       Impact factor: 2.493

2.  Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations.

Authors:  Natasha E Holmes; John D Turnidge; Wendy J Munckhof; James O Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Wei Gao; Keryn J Christiansen; Geoffrey W Coombs; Paul D R Johnson; Benjamin P Howden
Journal:  J Infect Dis       Date:  2011-08-01       Impact factor: 5.226

3.  Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet?

Authors:  Thomas L Holland; Vance G Fowler
Journal:  J Infect Dis       Date:  2011-08-01       Impact factor: 5.226

4.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Authors:  Vance G Fowler; Helen W Boucher; G Ralph Corey; Elias Abrutyn; Adolf W Karchmer; Mark E Rupp; Donald P Levine; Henry F Chambers; Francis P Tally; Gloria A Vigliani; Christopher H Cabell; Arthur Stanley Link; Ignace DeMeyer; Scott G Filler; Marcus Zervos; Paul Cook; Jeffrey Parsonnet; Jack M Bernstein; Connie Savor Price; Graeme N Forrest; Gerd Fätkenheuer; Marcelo Gareca; Susan J Rehm; Hans Reinhardt Brodt; Alan Tice; Sara E Cosgrove
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

5.  High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.

Authors:  Ravina Kullar; Susan L Davis; Donald P Levine; Jing J Zhao; Christopher W Crank; John Segreti; George Sakoulas; Sara E Cosgrove; Michael J Rybak
Journal:  Pharmacotherapy       Date:  2011-06       Impact factor: 4.705

6.  Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.

Authors:  Carol L Moore; Paola Osaki-Kiyan; Nadia Z Haque; Mary Beth Perri; Susan Donabedian; Marcus J Zervos
Journal:  Clin Infect Dis       Date:  2011-11-21       Impact factor: 9.079

7.  Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis.

Authors:  Sujata M Bhavnani; Christopher M Rubino; Paul G Ambrose; George L Drusano
Journal:  Clin Infect Dis       Date:  2010-06-15       Impact factor: 9.079

8.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-02-01       Impact factor: 9.079

Review 9.  Daptomycin: evaluation of a high-dose treatment strategy.

Authors:  Gary Wu; Teena Abraham; Jonathan Rapp; Fabienne Vastey; Nasser Saad; Eric Balmir
Journal:  Int J Antimicrob Agents       Date:  2011-05-06       Impact factor: 5.283

10.  Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  D P Levine; B S Fromm; B R Reddy
Journal:  Ann Intern Med       Date:  1991-11-01       Impact factor: 25.391
View more
  1 in total

1.  A GC-MS-based untargeted metabolomics approach for comprehensive metabolic profiling of vancomycin-induced toxicity in mice.

Authors:  Changmeng Cui; Li Zhu; Qian Wang; Ruijuan Liu; Dadi Xie; Yujin Guo; Dingyi Yu; Changshui Wang; Dan Chen; Pei Jiang
Journal:  Heliyon       Date:  2022-07-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.